<DOC>
	<DOC>NCT00979368</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics following single oral doses of BMS-816336 in healthy male subjects.</brief_summary>
	<brief_title>Safety Study of BMS-816336 in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Healthy male subjects BMI of 18 to 32 kg/m² Men only, ages 1855 years Sexually active men not using effective birth control if their partners are WOCBP Any significant acute or chronic medical illness Family history of Gilbert's disease History of Pancreatitis Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, EGG or clinical laboratory determinations QTc interval &gt; 450 msec (corrected for heart rate using Fridericia's correction method, QTcF) Second or thirddegree AV block or clinically relevant ECG abnormalities History of allergy to 11βHSD1 inhibitors or related compounds Prior exposure to BMS816336 Use of St. John's Wort (Hypericum) within 4 weeks prior to the first dose of study drug and throughout the study Use of an oral, injectable, inhalable or suspension of glucocorticoid agents within 12 weeks of study drug administration Use of any glucocorticoid topical creams within 4 weeks of study drug administration Use of oral, injectable, or topical androgen agent within 12 weeks prior to enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>